PubRank

Michael R Ehrenstein

Author PubWeight™ 60.45‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients. Immunity 2010 5.13
2 Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum 2006 3.11
3 Novel suppressive function of transitional 2 B cells in experimental arthritis. J Immunol 2007 3.09
4 Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum 2003 3.00
5 The classical pathway is the dominant complement pathway required for innate immunity to Streptococcus pneumoniae infection in mice. Proc Natl Acad Sci U S A 2002 2.72
6 An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 2002 2.54
7 Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta. J Exp Med 2007 2.47
8 The 'short' history of regulatory B cells. Trends Immunol 2007 2.38
9 Mice lacking endogenous IL-10-producing regulatory B cells develop exacerbated disease and present with an increased frequency of Th1/Th17 but a decrease in regulatory T cells. J Immunol 2011 2.31
10 CD19+CD24hiCD38hi B cells maintain regulatory T cells while limiting TH1 and TH17 differentiation. Sci Transl Med 2013 1.89
11 Impact of DNA ligase IV on nonhomologous end joining pathways during class switch recombination in human cells. J Exp Med 2005 1.84
12 Defects in CTLA-4 are associated with abnormal regulatory T cell function in rheumatoid arthritis. Proc Natl Acad Sci U S A 2008 1.69
13 Immunoglobulin M is required for protection against atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 2009 1.61
14 The efficacy of repeated treatment with B-cell depletion therapy in systemic lupus erythematosus: an evaluation. Rheumatology (Oxford) 2011 1.55
15 Germinal center B cells govern their own fate via antibody feedback. J Exp Med 2013 1.36
16 Adoptive therapy with redirected primary regulatory T cells results in antigen-specific suppression of arthritis. Proc Natl Acad Sci U S A 2009 1.34
17 Predominant role of IgM-dependent activation of the classical pathway in the clearance of dying cells by murine bone marrow-derived macrophages in vitro. Eur J Immunol 2005 1.29
18 Natural IgM is required for suppression of inflammatory arthritis by apoptotic cells. J Immunol 2011 1.14
19 Regulatory T-cells in systemic lupus erythematosus and rheumatoid arthritis. FEBS Lett 2011 1.09
20 Atorvastatin restores Lck expression and lipid raft-associated signaling in T cells from patients with systemic lupus erythematosus. J Immunol 2006 1.08
21 Statins for atherosclerosis--as good as it gets? N Engl J Med 2005 1.08
22 Selective ERK activation differentiates mouse and human tolerogenic dendritic cells, expands antigen-specific regulatory T cells, and suppresses experimental inflammatory arthritis. Arthritis Rheum 2011 1.08
23 Th17 cells are restrained by Treg cells via the inhibition of interleukin-6 in patients with rheumatoid arthritis responding to anti-tumor necrosis factor antibody therapy. Arthritis Rheum 2012 1.07
24 Atorvastatin inhibits autoreactive B cell activation and delays lupus development in New Zealand black/white F1 mice. J Immunol 2004 1.02
25 Natural serum IgM maintains immunological homeostasis and prevents autoimmunity. Springer Semin Immunopathol 2004 1.00
26 Elevated serum BAFF levels are associated with rising anti-double-stranded DNA antibody levels and disease flare following B cell depletion therapy in systemic lupus erythematosus. Arthritis Rheum 2013 0.98
27 Increased positive selection of B1 cells and reduced B cell tolerance to intracellular antigens in c1q-deficient mice. J Immunol 2007 0.96
28 Cutting edge: selection of B lymphocyte subsets is regulated by natural IgM. J Immunol 2002 0.94
29 The yin and yang of regulatory T cells and inflammation in RA. Nat Rev Rheumatol 2010 0.92
30 Abnormal CTLA-4 function in T cells from patients with systemic lupus erythematosus. Eur J Immunol 2010 0.91
31 Restoring the balance: harnessing regulatory T cells for therapy in rheumatoid arthritis. Eur J Immunol 2008 0.90
32 Regulatory T-cell adoptive immunotherapy: potential for treatment of autoimmunity. Expert Rev Clin Immunol 2011 0.88
33 Secreted IgM enhances B cell receptor signaling and promotes splenic but impairs peritoneal B cell survival. J Immunol 2010 0.87
34 Cells of the synovium in rheumatoid arthritis. B cells. Arthritis Res Ther 2007 0.85
35 B-cell numbers and phenotype at clinical relapse following rituximab therapy differ in SLE patients according to anti-dsDNA antibody levels. Rheumatology (Oxford) 2012 0.85
36 Tuberculosis and anti-TNF treatment: experience of a central London hospital. Clin Rheumatol 2010 0.84
37 Induced CD8+FoxP3+ Treg cells in rheumatoid arthritis are modulated by p38 phosphorylation and monocytes expressing membrane tumor necrosis factor α and CD86. Arthritis Rheumatol 2014 0.79
38 Therapeutic potential of Tregs to treat rheumatoid arthritis. Semin Immunol 2011 0.78
39 Access to the next wave of biologic therapies (Abatacept and Tocilizumab) for the treatment of rheumatoid arthritis in England and Wales: addressing treatment outside the current NICE guidance. Clin Rheumatol 2012 0.75
40 B cell depletion in systemic lupus erythematosus. Clin Med 2007 0.75